When was MyOme founded?

MyOme was founded in 2017 and raised its 1st funding round 5 years after it was founded.

Where is MyOme located?

MyOme is headquartered in San Carlos, United States.

Who is the current CEO of MyOme?

Premal Shah of MyOme. They have also founded 1 company and are angel investors in 4 startups, including Ciitizen and 6sense.

How many employees does MyOme have?

As of Aug 31, 2026, the latest employee count at MyOme is 97.

Is MyOme a funded company?

MyOme is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on Jun 21, 2022.

When was the latest funding round of MyOme?

MyOme's latest funding was a $***** Series B round on Jun 21, 2022, with participation from 6 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.31B in funding in 2026 to date.

Where does MyOme rank among its competitors?

MyOme ranks 5th amongst 179 active competitors, of which 28 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Genomind, which secured $400K in Feb, 2025.

Who are the top competitors of MyOme?

MyOme's top competitors include 23andMe, Helix and Color. Among them, Genomind secured the most recent funding round in February, 2025.

MyOme - 2026 Company Profile, Team, Funding & Competitors

MyOme is a series B company based in San Carlos (United States), founded in 2017 by Matthew Rabinowitz, Akash Kumar and Oren Schaedel. It operates as a Provider of a platform for gene analysis to determine genetic diseases and drug response. MyOme has raised $36M in funding from Healthcare Ventures. The company has 179 active competitors, including 28 funded and 13 that have exited. Its top competitors include companies like 23andMe, Helix and Color.

Company Details

Provider of a platform for gene analysis to determine genetic diseases and drug response. The company uses whole-genome sequencing that determines a genome risk score that provides information regarding a variety of common diseases like heart disease and rare disorders that is impacted by many genetic factors. The company also offers whole-genome analysis to embryo selection in IVF.

Website: myome.com
Email ID: *****@myome.com
Phone Number: +1 **********

Key Metrics

Founded Year

2017

Location

San Carlos, United States

Stage

Series B

Total Funding

$36M in 1 round

Latest Funding Round

Series B, Jun 21, 2022, $*****

Investors

Healthcare Ventures & 6 more

Ranked

5^th among 179 active competitors

Employee Count

97 as on Aug 31, 2026

Similar Companies

23andMe & 482 more

View MyOme's full profile

MyOme is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
MyCarrier TMS CIN: 46-5766459 , United States, Active	Dec 31, 2016	-	-	-

MyOme has raised a total funding of $36M over 1 round. Its latest funding round was a Series B round on Jun 21, 2022 for $*****. 6 investors participated in its latest round. MyOme has 7 institutional investors.

Here is the list of recent funding rounds of MyOme:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 21, 2022	8138558	Series B	9382157	3923589	7333057	1419111

Access funding benchmarks and valuations. Sign up today!

View details of MyOme's funding rounds and investors

The founders of MyOme are Matthew Rabinowitz, Akash Kumar and Oren Schaedel.

Here are the details of MyOme's key team members:

Matthew Rabinowitz: Co-Founder & Chairman of MyOme and founder of 1 other company.
Contact Info: 1 email address
Akash Kumar: Co-Founder & Chief Medical & Scientific Officer of MyOme.
Contact Info: 1 email address
Oren Schaedel: Former Co-Founder of MyOme.
Premal Shah: Co-Founder & COO of MyOme and founder of 2 other companies, 6sense and grepdata.com. They are also an angel investor in 4 startups.
Contact Info: 1 email address

View details of MyOme's Founder profiles and Board Members

MyOme's employee count trend

MyOme has 97 employees as of Aug 26. Here is MyOme's employee count trend over the years:

Uncover MyOme's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of MyOme include 23andMe, Helix and Color. Here is the list of Top 10 competitors of MyOme, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	23andMe 2006, Sunnyvale (United States), Acquired	Provider of genetic test solutions to study ancestry, genealogy, and inherited traits	$944M	Fidelity Investments, Google Ventures & 35 others	77/100
2nd	Helix 2015, San Francisco (United States), Series E	Provider of a genomic database for clinical research	$435M	DFJ Growth, Kleiner Perkins & 12 others	71/100
3rd	Color 2013, Burlingame (United States), Series E	Provider of end-to-end Virtual clinic offering cancer-based solutions	$491M	General Catalyst, T. Rowe Price & 46 others	66/100
4th	Nucleus Genomics 2021, Manhattan (United States), Series A	Provider of genetic testing kits for rare variant analysis	$32M	Founders Fund, Giant Step Capital & 27 others	62/100
5th	MyOme 2017, San Carlos (United States), Series B	Provider of a platform for gene analysis to determine genetic diseases and drug response	$36M	Foresite Capital, SoftBank & 5 others	61/100
6th	Genomind 2009, King Of Prussia (United States), Series C	Developer of genetic tests for personalised medicines to enhance mental health treatment	$64.4M	Claritas Capital, SVB & 1 others	56/100
7th	Veritas Genetics 2014, Danvers (United States), Acquired	Provider of genetic testing products	$53.4M	Trustbridge Partners, Simcere Pharma & 6 others	55/100
8th	Segterra (InsideTracker) 2009, Cambridge (United States), Series B	Personalized path for health, wellness, and performance applications	$17.5M	PeakBridge, BASF & 4 others	55/100
9th	Counsyl 2007, San Francisco (United States), Acquired	DNA mapping for pre-pregnancy genetic testing, DNA and cancer screening	$113M	Perceptive Advisors, Goldman Sachs & 14 others	54/100
10th	SelfDecode 2016, San Luis Obispo (United States), Series A	Provider of personal genome analysis service	$8M	BoxOne Ventures & 2 others	50/100